With a no-deal Brexit still a real possibility, Merck continues to prepare for the worst case scenario.

The uncertainty surrounding the UK’s future with Europe is having a measurable effect on pharma. But it looks like the end is nowhere in sight.

We sit down with Nigel Theobald, Chief Executive, N4 Pharma. He tells us the story of his career and offers some advice for budding entrepreneurs.

Our animation explores the unique challenges a "no-deal" Brexit poses for the drug development and advanced therapy sectors.

The cannabis business is booming as century-old legal conventions restricting use begin to unravel. Can pharma ride the wave?

We are delighted to announce that The Medicine Maker Power List 2019 is here!

There are few things more inspirational than someone making a positive difference without the need for recognition – but you have to find them first.

A new AI platform aims to harness scientific data for improved drug development.

EU will allow companies to carry out QC testing in the UK after a "no deal" Brexit, at least under certain conditions and for a limited time.

Nick Crabb explains the UK’s health technology assessment agency's (NICE's) approach to cell and gene therapies.